Wells Fargo & Company MN Buys 12,517 Shares of LivaNova PLC (NASDAQ:LIVN)

Wells Fargo & Company MN increased its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 6.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 220,782 shares of the company's stock after acquiring an additional 12,517 shares during the quarter. Wells Fargo & Company MN owned approximately 0.41% of LivaNova worth $10,224,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Trexquant Investment LP raised its holdings in LivaNova by 139.7% during the 4th quarter. Trexquant Investment LP now owns 101,653 shares of the company's stock worth $4,708,000 after buying an additional 59,241 shares during the period. Wellington Management Group LLP acquired a new stake in shares of LivaNova during the fourth quarter valued at approximately $8,897,000. Pictet Asset Management Holding SA lifted its position in shares of LivaNova by 24.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 7,353 shares of the company's stock valued at $341,000 after acquiring an additional 1,441 shares in the last quarter. Norges Bank acquired a new position in LivaNova in the 4th quarter worth approximately $3,925,000. Finally, JPMorgan Chase & Co. boosted its stake in LivaNova by 95.7% in the 4th quarter. JPMorgan Chase & Co. now owns 387,772 shares of the company's stock worth $17,958,000 after purchasing an additional 189,665 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Up 2.5 %

Shares of LIVN traded up $0.85 during mid-day trading on Tuesday, hitting $35.46. 390,562 shares of the company's stock were exchanged, compared to its average volume of 626,167. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 84.43 and a beta of 0.90. The firm has a fifty day moving average of $39.58 and a two-hundred day moving average of $46.46. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Mizuho reduced their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group lowered their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Finally, Wolfe Research lowered shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.